Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI

Anquetil, Céline; Abdelhamid, S.; Gélis, Anthony; Fattal, Charles

doi:10.1038/sc.2016.49

Cited by 22 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study, by Anquetil et al, evaluated differences in QoL between patients with a history of augmentation cystoplasty and those receiving botulinum toxin using the full Qualiveen questionnaire to compare groups. Patients with augmentation ( n = 16) had improved overall QoL, as well as improvement in the subdomain of Limitations and Constraints compared to those using botulinum toxin ( n = 14).…”

Section: Discussionmentioning

confidence: 99%

“…Improved bladder function may decrease inconvenience, encouraging patients to continue CIC rather than transitioning to less ideal bladder managements. Prior studies, which compared QoL between patients performing CIC and those patients who perform CIC and use botulinum toxin or have undergone augmentation cystoplasty were limited by small sample sizes and were underpowered to compare between the three treatments …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of augmentation cystoplasty and botulinum toxin injection on patient‐reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization

Myers

Lenherr

Stoffel

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims Clean intermittent catheterization (CIC) is recommended after spinal cord injury (SCI) because it has the least complications, however, CIC has a high discontinuation rate. We hypothesized that bladder botulinum toxin injection or augmentation cystoplasty may improve satisfaction with CIC. Methods The NBRG registry is a multicenter, prospective, observational study asking SCI participants about neurogenic bladder (NGB) related quality of life (QoL). In this study, participants performing CIC as primary bladder management were categorized into 3 groups: (1) CIC alone (CIC); (2) CIC with botulinum toxin (CIC‐BTX); and (3) CIC with augmentation cystoplasty (CIC‐AUG). Outcomes included primary: Neurogenic Bladder Symptom Score (NBSS) and SCI‐QoL Bladder Management Difficulties, and secondary: NBSS subdomains (Incontinence, Storage & Voiding, Consequences) and the NBSS final question (satisfaction with urinary function). Multivariable regression, controlling for multiple factors was used to establish differences between the three groups. Results Eight hundred seventy‐nine participants performed CIC as primary bladder management and had the following characteristics: mean age 43.4 (±12.9) and years from injury 13.7 (±10.7), tetraplegia in 284 (32%), and 543 (62%) were men. Bladder management was CIC in 593 (67%), CIC‐BTX in 161 (19%), and CIC‐AUG in 125(15%). Primary outcomes: CIC‐AUG had associated improved total NBSS versus CIC(−3.2(−5.2 to −1.2), P = 0.001 and CIC‐BTX(−3.9(−6.3 to −1.6), P = 0.001), CIC‐AUG also had better SCI‐QoL Difficulties scores versus CIC(−4(−5.48 to −2.53, P < 0.001) and CIC‐BTX(−4.4(−6.15 to −2.65, P < 0.001). Secondary outcomes: CIC‐AUG had associated improved Incontinence and Satisfaction scores versus CIC and CIC‐BTX. Conclusions Compared to patients performing CIC with or without botulinum toxin treatment, those with augmentation cystoplasty had associated better urinary function and satisfaction with their urinary symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effects of augmentation cystoplasty and botulinum toxin injection on patient‐reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization

Myers

Lenherr

Stoffel

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Contemporary evidence for the comparative safety and efficacy of the two techniques in patients with neurogenic detrusor overactivity was recently published by Anquetil and co-workers. 9 They treated 31 patients with either botulinum toxin and cystoplasty and included a mean follow-up of 9.94 years (cystoplasty) and 6.63 years (botulinum toxin). Both quality of life and continence rates were found to be significantly better in those undergoing cystoplasty with a similar occurrence of urinary infection and stones in both groups.…”

Section: Discussionmentioning

confidence: 99%

Augmentation cystoplasty in neuropathic bladder

Reid

Tophill

Osman

et al. 2018

The Journal of Spinal Cord Medicine

View full text Add to dashboard Cite

In this series, we review 51 consecutive patients undergoing the same operation over a 10-year period from 2004 to 2014 in the same single unit. Outcome measures: Demographic data were collected to include patient age, condition, and previous treatments. Pre-and post-operative details included sphincter insertions, renal function, continence rates, and complications. Results: Despite an increase in the number of patients seen at the unit, there were considerably fewer cystoplasty procedures performed in the current series (51 vs. 78 in the 1982-1992 series). There were also significantly fewer patients with spina bifida and fewer concomitant sphincter insertions in the latter series (eight patients vs. 52 in the 82/92 series). Nevertheless, similar outcomes are observed between the current and 1982-1992 series, with continence rates of 93.7 and 93.6%, respectively and low numbers of reported adverse events for both retrospective cohorts. Conclusions: Cystoplasty remains a safe and effective option for the management of neuropathic bladder in a carefully selected group of patients.

show abstract

“…However, CIC remains mandatory for periodic emptying of the bladder [6]. Other studies have noted that this treatment decreased AD and significantly improved quality of life among patients with who had DSD [27,33].…”

Section: Botulinum Toxin a For Neurogenic Detrusor Overactivitymentioning

confidence: 99%

Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction

Jiang

Chen

2020

Int Neurourol J

View full text Add to dashboard Cite

Patients with neurogenic lower urinary tract dysfunction (NLUTD) experience urinary incontinence with or without difficult urination, which might promote recurrent urinary tract infection (UTI) and exacerbate upper urinary tract function. Nonetheless, appropriate bladder management has been shown to reduce urological complications and improve quality of life. In addition to pharmacological therapy and surgical intervention, botulinum toxin A (BoNT-A) has been widely utilized in NLUTD. The therapeutic efficacy of detrusor BoNT-A injections for neurogenic detrusor overactivity due to spinal cord injury (SCI), multiple sclerosis, or other central nervous system lesions, such as cerebrovascular accident, Parkinson disease, early dementia, and pediatric NLUTD due to myelomeningocele, has been well established, with repeated BoNT-A injections every 6 to 9 months being necessary to maintain its therapeutic effects. Urethral BoNT-A injection can decrease urethral sphincter resistance and facilitate efficient voiding in patients with NLUTD who wish to preserve self-voiding. Detrusor BoNT-A injection can also decrease the occurrence of autonomic dysreflexia in patients with SCI, even after failed augmentation enterocystoplasty, with additional benefits including reduced UTI episodes and preserved renal function with repeated injections. However, this treatment does have some side effects. Complete informed consent for BoNT-A injection therapy with full disclosure of its potential complications should therefore be obtained before this procedure is undertaken.

show abstract

Botulinum toxin therapy for neurogenic detrusor hyperactivity versus augmentation enterocystoplasty: impact on the quality of life of patients with SCI

Abstract: QoL was found to be higher with an AC compared with BT injections. Long-time intervals between two injections and advantages specific to AC might explain in part these findings.

Cited by 22 publications

References 21 publications

The effects of augmentation cystoplasty and botulinum toxin injection on patient‐reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization

The effects of augmentation cystoplasty and botulinum toxin injection on patient‐reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization

Augmentation cystoplasty in neuropathic bladder

Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction

Contact Info

Product

Resources

About